Want to see BOLT full AI Analyst Report?
Total Valuation
Bolt Biotherapeutics has a market cap or net worth of $7.06M. The enterprise value is $10.33.
Market Cap$7.06M
Enterprise Value$10.33
Share Statistics
Bolt Biotherapeutics has 1,926,345 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding1,926,345
Owned by Insiders2.28%
Owned by Institutions20.46%
Financial Efficiency
Bolt Biotherapeutics’s return on equity (ROE) is -1.26 and return on invested capital (ROIC) is -67.72%.
Return on Equity (ROE)-1.26
Return on Assets (ROA)-0.59
Return on Invested Capital (ROIC)-67.72%
Return on Capital Employed (ROCE)-0.72
Revenue Per Employee334.57K
Profits Per Employee-1.45M
Employee Count23
Asset Turnover0.14
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Bolt Biotherapeutics is ―. Bolt Biotherapeutics’s PEG ratio is -0.00031.
PE Ratio―
PS Ratio1.33
PB Ratio0.39
Price to Fair Value0.39
Price to FCF-0.26
Price to Operating Cash Flow-0.20
PEG Ratio-0.00031
Income Statement
In the last 12 months, Bolt Biotherapeutics had revenue of 7.70M and earned -33.38M in profits. Earnings per share was -17.85.
Revenue7.70M
Gross Profit6.20M
Operating Income-34.63M
Pretax Income-33.38M
Net Income-33.38M
EBITDA-31.89M
Earnings Per Share (EPS)-17.85
Cash Flow
In the last 12 months, operating cash flow was -31.45M and capital expenditures -85.00K, giving a free cash flow of -31.54M billion.
Operating Cash Flow-31.45M
Free Cash Flow-31.54M
Free Cash Flow per Share-16.37
Dividends & Yields
Bolt Biotherapeutics pays an annual dividend of $0.09, resulting in a dividend yield of ―
Dividend Per Share$0.09
Dividend Yield―
Payout Ratio―
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.37
52-Week Price Change-32.63%
50-Day Moving Average3.96
200-Day Moving Average4.78
Relative Strength Index (RSI)48.46
Average Volume (3m)29.18K
Important Dates
Bolt Biotherapeutics upcoming earnings date is Nov 5, 2026, After Close (Confirmed).
Last Earnings DateAug 11, 2026
Next Earnings DateNov 5, 2026
Ex-Dividend Date―
Financial Position
Bolt Biotherapeutics as a current ratio of 3.59, with Debt / Equity ratio of 171.08%
Current Ratio3.59
Quick Ratio3.59
Debt to Market Cap0.00
Net Debt to EBITDA-0.35
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Bolt Biotherapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Bolt Biotherapeutics EV to EBITDA ratio is -0.67, with an EV/FCF ratio of -0.54.
EV to Sales2.79
EV to EBITDA-0.67
EV to Free Cash Flow-0.54
EV to Operating Cash Flow-0.54
Balance Sheet
Bolt Biotherapeutics has $17.60M in cash and marketable securities with $21.62M in debt, giving a net cash position of -$4.03M billion.
Cash & Marketable Securities$17.60M
Total Debt$21.62M
Net Cash-$4.03M
Net Cash Per Share-$2.09
Tangible Book Value Per Share$14.17
Margins
Gross margin is 95.68%, with operating margin of -450.07%, and net profit margin of -433.74%.
Gross Margin95.68%
Operating Margin-450.07%
Pretax Margin-433.74%
Net Profit Margin-433.74%
EBITDA Margin-414.36%
EBIT Margin-433.74%
Analyst Forecast
The average price target for Bolt Biotherapeutics is $14.50, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$14.50
Price Target Upside278.59% Upside
Analyst ConsensusModerate Buy
Analyst Count3
Revenue Growth Forecast12.79%
EPS Growth Forecast37.93%